Evidence map›Paper›PMID 38197869›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2024

A New Twist on a Classic: Enhancing Radioiodine Uptake in Advanced Thyroid Cancer.

Melissa G Lechner, Gregory A Brent

Open access · bronzeAbstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Melissa G LechnerDivision of Endocrinology, Diabetes, and Metabolism, Department of Medicine, UCLA David Geffen School of Medicine, Los Angeles, California.ORCID 0000-0002-4744-6566
Gregory A BrentDivision of Endocrinology, Diabetes, and Metabolism, Department of Medicine, UCLA David Geffen School of Medicine, Los Angeles, California.ORCID 0000-0002-4638-6645
University of California, Los Angeles · US

Funding

Mechanisms of Thyroid Autoimmunity in Checkpoint ImmunotherapyK08DK129829 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LECHNER, MELISSA G · 2021 to 2025
$878k
Thyroid Hormone and Retinoic Acid Regulation of Gene ExpressionI01BX001966 · VA · VA GREATER LOS ANGELES HEALTHCARE SYSTEM · PI BRENT, GREGORY A · 2014 to 2025
–
BLRD VA I01 BX001966NIDDK NIH HHS K08 DK129829
6 · The paper itself

Abstract

Advanced differentiated thyroid cancer that is resistant to radioactive iodine therapy may become responsive with a unique treatment combination of chloroquine and vorinostat. This treatment was demonstrated in cellular and animal models of thyroid cancer to inhibit endocytosis of the plasma membrane-bound iodine transporter, NIS, and restore iodine uptake. See related article by Read et al., p. 1352.

Indexed as

IodineSymportersThyroid NeoplasmsAnimalsIodine RadioisotopesIodineIodine RadioisotopesSymporters

Identifiers

PMID38197869
PMCPMC10984766
OpenAlexW4390704617

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.